Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)

NCT06879145 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

840

Enrollment

INDUSTRY

Sponsor class

Conditions

Muscular Invasive Bladder Cancer (MIBC)

Interventions

DRUG: SHR-A2102；Adebrelimab

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.